These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25692618)

  • 1. Structural studies reveal thalidomide's mechanism of action and clinical effects: crystal clear or clearly complexed?
    Ley AM; Chau CH; Figg WD
    Cancer Biol Ther; 2015; 16(1):19-20. PubMed ID: 25692618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A peek into the atomic details of thalidomide's clinical effects.
    Bhogaraju S; Dikic I
    Nat Struct Mol Biol; 2014 Sep; 21(9):739-40. PubMed ID: 25192261
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
    Bodera P; Stankiewicz W
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide-a notorious sedative to a wonder anticancer drug.
    Zhou S; Wang F; Hsieh TC; Wu JM; Wu E
    Curr Med Chem; 2013; 20(33):4102-8. PubMed ID: 23931282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thalidomide, cereblon and multiple myeloma].
    Ogura T
    Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
    Yamamoto T; Shibata N; Sukeguchi D; Takashima M; Nakamura S; Toru T; Matsunaga N; Hara H; Tanaka M; Obata T; Sasaki T
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3973-6. PubMed ID: 19297157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of thalidomide and its derivatives.
    Ito T; Handa H
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMiDs New and Old.
    Yamshon S; Ruan J
    Curr Hematol Malig Rep; 2019 Oct; 14(5):414-425. PubMed ID: 31302872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strengthening Molecular Glues: Design Strategies for Improving Thalidomide Analogs as Cereblon Effectors and Anticancer Agents.
    Nutt MJ; Stewart SG
    Drug Discov Today; 2024 Jun; 29(6):104010. PubMed ID: 38704021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.
    Sissung TM; Thordardottir S; Gardner ER; Figg WD
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1058-69. PubMed ID: 19719457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunomodulatory drugs (IMiDs)].
    Oshima K; Ichinohe T
    Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose thalidomide in myeloma: efficacy and biologic significance.
    Durie BG
    Semin Oncol; 2002 Dec; 29(6 Suppl 17):34-8. PubMed ID: 12520483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide mimics uridine binding to an aromatic cage in cereblon.
    Hartmann MD; Boichenko I; Coles M; Zanini F; Lupas AN; Hernandez Alvarez B
    J Struct Biol; 2014 Dec; 188(3):225-32. PubMed ID: 25448889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
    Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
    Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide Teratogenic Effects Linked to Degradation of SALL4: After 60 years, researchers have now shed light on the mechanism underlying thalidomide's devastating teratogenic effects.
    Am J Med Genet A; 2018 Dec; 176(12):2538-2539. PubMed ID: 30597765
    [No Abstract]   [Full Text] [Related]  

  • 17. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
    Shortt J; Hsu AK; Johnstone RW
    Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
    Eichner R; Heider M; Fernández-Sáiz V; van Bebber F; Garz AK; Lemeer S; Rudelius M; Targosz BS; Jacobs L; Knorn AM; Slawska J; Platzbecker U; Germing U; Langer C; Knop S; Einsele H; Peschel C; Haass C; Keller U; Schmid B; Götze KS; Kuster B; Bassermann F
    Nat Med; 2016 Jul; 22(7):735-43. PubMed ID: 27294876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.
    Kenyon BM; Browne F; D'Amato RJ
    Exp Eye Res; 1997 Jun; 64(6):971-8. PubMed ID: 9301478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide treatment in multiple myeloma.
    Strasser K; Ludwig H
    Blood Rev; 2002 Dec; 16(4):207-15. PubMed ID: 12350364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.